Futibatinib was approved by the FDA in 2022 for the treatment of previously treated, unresectable, locally advanced or metastatic intrahepatic CCA harboring FGFR2 gene fusions or other rearrangements.16 Additionally, infigratinib was approved in 2021 as a second-line treatment option for patients with locally advanced or metastatic CCA harboring an FGFR2 fusion or rearrangement,17 although it was later withdrawn from the market in 2023.18 Here, FGFR2 is linked to cholangiocarcinoma.